Clinical study demonstrates Probi’s new dual-strain probiotic significantly improves occasional constipation in healthy adults

Probi, part of the Symrise Group, has announced new clinical evidence demonstrating that its new dual-strain probiotic formulation consisting of the proprietary strain LP299V® and LpGOS42^TM delivers statistically significant improvements in bowel regularity, stool consistency and digestive comfort.

The randomized, placebo-controlled study evaluated a combination of Lactiplantibacillus plantarum 299v (LP299V) and Lactiplantibacillus plantarum GOS42 (LpGOS42), two patent-protected strains developed by Probi.

While LP299V is already well documented for its benefits in individuals with irritable bowel syndrome, this is the first clinical trial to investigate the complementary effects of combining LP299V with LpGOS42 in otherwise healthy adults experiencing occasional constipation.

The 8-week study, conducted in London, Canada, included 100 healthy adults reporting occasional constipation. Participants receiving the new dual-strain formulation experienced statistically significant improvement compared to placebo.

• Improved stool consistency
• A higher percentage of complete spontaneous bowel movements (CSBMs) without hard or lumpy stools
• Reduced flatulence
• Improved quality of life, particularly in satisfaction-related domains 

A focused post hoc analysis provided further insight. Among participants reporting three or fewer weekly bowel movements at baseline, which represents 80% of the study population, those receiving the dual-strain combination achieved a significantly greater increase in weekly CSBMs compared to placebo.

The study concludes that daily supplementation with LP299V and LpGOS42 over eight weeks leads to measurable, statistically significant improvements in bowel function, digestive comfort, and satisfaction with bowel movement regularity in healthy adults with occasional constipation.

“Constipation affects an estimated 12% of the global population and can significantly impair daily comfort and overall well-being,” says Christina Vegge, VP Research & Development at  Probi. “This study demonstrates that a combination of carefully selected probiotic strains can deliver clinically meaningful improvements in bowel regularity and digestive comfort in healthy individuals, offering a science-based, non-pharmaceutical solution for occasional constipation.”

With this new data, Probi further strengthens its clinically substantiated health platform and reinforces its strategy of developing targeted, strain-specific probiotic solutions backed by human clinical research. The new dual-strain formulation is available for global B2B partnerships across dietary supplements and functional nutrition applications.

By combining documented strains with complementary mechanisms of action, Probi continues to advance probiotic innovation designed to address defined consumer health needs with robust scientific validation.

To learn more click here.

For further information, please contact:

Christina Vegge, Vice President R&D, Probi, christina.vegge@probi.com